Since the November 2007 FDA ordered Black Box Warning for Avandia, the popular drug used to treat type II diabetes has been linked to over 83,000 heart attacks. The FDA’s own research showed Avandia to be associated with a significant increase in heart attack risk, but have yet to issue a recall of this drug.
The AMA also admitted Avandia was dangerous. In its journal “Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone (avandia) use for at least 12 months is associated with a significantly increase risk of myocardial infarction.”
The New England Journal of Medicine also warned about the safety of the drug. Despite these multiple warnings, an FDA panel voted 22-1 in favor of keeping Avandia on the market.